Cargando…

A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that typically results in death within 2–5 years of initial symptom onset. Multidisciplinary ALS clinics (MDCs) have been established to provide specialty care to people living with the disease. OBJECTIVE: To estimate th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horton, D. Kevin, Graham, Shannon, Punjani, Reshma, Wilt, Grete, Kaye, Wendy, Maginnis, Kimberly, Webb, Lauren, Richman, Judy, Bedlack, Richard, Tessaro, Edward, Mehta, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815888/ https://www.ncbi.nlm.nih.gov/pubmed/29262737 http://dx.doi.org/10.1080/21678421.2017.1406953

Ejemplares similares

Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009–2011 and survival characteristics through 2015
por: PUNJANI, RESHMA, et al.
Publicado: (2019)

Prevalence of Amyotrophic Lateral Sclerosis — United States, 2015
por: Mehta, Paul, et al.
Publicado: (2018)

Prevalence of Amyotrophic Lateral Sclerosis — United States, 2014
por: Mehta, Paul, et al.
Publicado: (2018)

CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions
por: Mehta, Paul, et al.
Publicado: (2017)

Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry’s Research Notification Mechanism
por: Mehta, Paul, et al.
Publicado: (2021)

Preliminary Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey Data
por: Bryan, Leah, et al.
Publicado: (2016)

Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017
por: MEHTA, PAUL, et al.
Publicado: (2023)

Amyotrophic Lateral Sclerosis (ALS) Awareness Month — May 2013
Publicado: (2013)

Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): A national, cross-sectional study
por: Zizzi, Christine, et al.
Publicado: (2022)

State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance
por: Wagner, Laurie, et al.
Publicado: (2016)

Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015
por: RAYMOND, JAIME, et al.
Publicado: (2019)

Motoneuron firing in amyotrophic lateral sclerosis (ALS)
por: de Carvalho, Mamede, et al.
Publicado: (2014)

Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors
por: Sebastião, Ana M., et al.
Publicado: (2018)

Saccadic intrusions in amyotrophic lateral sclerosis (ALS)
por: Becker, Wolfgang, et al.
Publicado: (2019)

Characteristics of Sensory Neuron Dysfunction in Amyotrophic Lateral Sclerosis (ALS): Potential for ALS Therapy
por: Seki, Soju, et al.
Publicado: (2023)

How common are ALS plateaus and reversals?
por: Bedlack, Richard S., et al.
Publicado: (2016)

Alterations in Leptin Signaling in Amyotrophic Lateral Sclerosis (ALS)
por: Ferrer-Donato, Agueda, et al.
Publicado: (2021)

Correction to Chu et al. (2013)
Publicado: (2014)

Correction to Booth et al. (2013)
Publicado: (2013)

Incidence and Geographical Variation of Amyotrophic Lateral Sclerosis (ALS) in Southern Germany – Completeness of the ALS Registry Swabia
por: Uenal, Hatice, et al.
Publicado: (2014)

Environmental Risk Factors and Amyotrophic Lateral Sclerosis (ALS): A Case-Control Study of ALS in Michigan
por: Yu, Yu, et al.
Publicado: (2014)

Retinal thinning in amyotrophic lateral sclerosis patients without ophthalmic disease
por: Mukherjee, Nisha, et al.
Publicado: (2017)

Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS)
por: Mavlyutov, Timur A., et al.
Publicado: (2015)

Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design
por: Fournier, Christina N.
Publicado: (2022)

Evaluation of aerial microbial pollutants in Al-Haram Al-Nabawi during pilgrimage of 2013
por: Alananbeh, Kholoud M., et al.
Publicado: (2017)

Intronic NEFH variant is associated with reduced risk for sporadic ALS and later age of disease onset
por: Theunissen, Frances, et al.
Publicado: (2022)

ALS2 mutations: Juvenile amyotrophic lateral sclerosis and generalized dystonia
por: Sheerin, Una-Marie, et al.
Publicado: (2014)

Genetics and Sex in the Pathogenesis of Amyotrophic Lateral Sclerosis (ALS): Is There a Link?
por: Trojsi, Francesca, et al.
Publicado: (2020)

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
por: Park, Jin-Mo, et al.
Publicado: (2019)

MRI Study of Paraspinal Muscles in Patients with Amyotrophic Lateral Sclerosis (ALS)
por: Diamanti, Luca, et al.
Publicado: (2020)

The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS)
por: Ferrer‐Donato, Agueda, et al.
Publicado: (2021)

Delivery of nutritional management services to people with amyotrophic lateral sclerosis (ALS)
por: Halliday, Vanessa, et al.
Publicado: (2021)

Analysis of Biospecimen Demand and Utilization of Samples from the National Amyotrophic Lateral Sclerosis Biorepository
por: Bledsoe, Marianna J., et al.
Publicado: (2021)

Evaluating the completeness of the national ALS registry, United States
por: KAYE, WENDY E., et al.
Publicado: (2017)

The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice
por: Akamatsu, Megumi, et al.
Publicado: (2016)

The complexity of multidisciplinary respiratory care in amyotrophic lateral sclerosis
por: Berlowitz, David J., et al.
Publicado: (2023)

“Patients with amyotrophic lateral sclerosis (ALS) are usually nice persons”—How physicians experienced in ALS see the personality characteristics of their patients
por: Mehl, Theresa, et al.
Publicado: (2016)

Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients
por: Burkhardt, Christian, et al.
Publicado: (2017)

The Dyspnea-ALS-Scale (DALS-15) optimizes individual treatment in patients with amyotrophic lateral sclerosis (ALS) suffering from dyspnea
por: Vogt, Susanne, et al.
Publicado: (2019)

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)
por: Yunusova, Yana, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ojosgv5u8178cepsgm7e259hrh